Shots:
- The US FDA has approved Vizz (1.44% aceclidine ophthalmic solution) for the treatment of presbyopia in adults; samples are expected in the US by Oct 2025, with full commercial launch by mid-Q4’25
- Approval was based on the 3 P-III trials: CLARITY 1 & 2 evaluating Vizz (QD) in 466 pts for 42 days as well as CLARITY 3 to assess long term safety of Vizz in 217 pts for 6mos.
- In both CLARITY 1 & 2, Vizz met all 1 & 2EPs, showing rapid near vision improvement within 30min., lasting up to 10hrs., with consistent & reproducible results across both trials
Ref: GlobeNewswire | Image: LENZ Therapeutics | Press Release
Related News:- LENZ Therapeutics Collaborates with Lotus Pharmaceutical to Commercialize LNZ100 in the Republic of Korea and Southeast Asia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
